Texas is sidestepping a gridlocked federal system to tackle the opioid crisis, committing $100 million in state funds to launch FDA-track clinical trials for Ibogaine. The initiative marks a radical departure from federal drug policy and traditional pharmaceutical development.
W. Bryan Hubbard and former Governor Rick Perry secured the funding by framing the psychedelic as essential care for veterans with traumatic brain injuries. They argue pharmaceutical companies have no incentive to develop a one-dose cure for addiction. By funding the trial directly, Texas aims to prove Ibogaine's efficacy and safety to the FDA on its own terms.
The clinical case hinges on Ibogaine's unique neuroregenerative capacity. Research indicates it repairs physical brain damage and opens a 90 to 120-day window of neuroplasticity, far exceeding alternatives like ketamine. Rick Perry cites studies showing an 85% success rate in interrupting opioid addiction within 72 hours of a single dose.
Rick Perry, The Joe Rogan Experience:
- You can get 85% of the people who are hooked on opioids clean in 72 hours.
- That's such a stunning thing to me.
The political shift is as significant as the medical one. Perry, a former "tough on crime" drug warrior, now advocates for psychedelics as a moral obligation to veterans "anesthetized" by VA-prescribed opioids. This reframing has neutralized decades of stigma, winning over conservative legislatures.
Texas is not acting alone. Mississippi passed its own initiative with near-unanimous votes, allocating $5 million from opioid settlement funds. Tennessee, Missouri, Oklahoma, Louisiana, Kentucky, and West Virginia have active legislation to join. The movement is coalescing into a state-led challenge to federal drug scheduling.
W. Bryan Hubbard, The Joe Rogan Experience:
- I can confirm that the great state of Texas is going to fully fund the Texas Ibogaine initiative.
- It decided on its own to commit a full $100 million to launch the development of Ibogaine all the way through the FDA's drug development process.
The initiative faces a final hurdle: the DEA's current interpretation of federal right-to-try laws blocks access to Schedule I substances like Ibogaine. Texas's $100 million bet is a direct challenge to that barrier, aiming to force a policy change by demonstrating a treatment that works.

